tbuckley/cabot-search huggingface dataset:
PH‐Triggered, Lymph Node Focused Immunodrug Release by Polymeric 2‐Propionic‐3‐Methyl‐maleic Anhydrides with Cholesteryl End Groups
Authors: Alina G. Heck, Carolina Medina‐Montano, Zifu Zhong, Kim Deswarte, Katharina Eigen, Judith Stickdorn, Johannes Kockelmann, Maximilian Scherger, Niek N. Sanders, Stefan Lienenklaus, Bart N. Lambrecht, Stephan Grabbe, Bruno G. De Geest, Lutz Nuhn
Journal: Advanced Healthcare Materials (2024)

Abstract Gaining spatial control over innate immune activation is of great relevance during vaccine delivery and anticancer therapy, where one aims at activating immune cells at draining lymphoid tissue while avoiding systemic off‐target innate immune activation. Lipid‐polymer amphiphiles show high tendency to drain to lymphoid tissue upon local administration. Here, pH‐sensitive, cholesteryl end group functionalized polymers as stimuli‐responsive carriers are introduced for controlled immunoactivation of draining lymph nodes. Methacrylamide‐based monomers bearing pendant 2‐propionic‐3‐methylmaleic anhydride groups are polymerized by Reversible Addition‐Fragmentation Chain Transfer (RAFT) polymerization using a cholesterol chain‐transfer agent (chol‐CTA). The amine‐reactive anhydrides are conjugated with various amines, however, while primary amines afforded irreversible imides, secondary amines provided pH‐responsive conjugates that are released upon acidification. This can be applied to fluorescent dyes for irreversibly carrier labeling or immunostimulatory Toll‐like receptor (TLR) 7/8 agonists as cargos for pH‐responsive delivery. Hydrophilization of remaining anhydride repeating units with short PEG‐chains yielded cholesteryl‐polymer amphiphiles that showed efficient cellular uptake and increased drug release at endosomal pH. Moreover, reversibly conjugated TLR 7/8 agonist amphiphiles efficiently drained to lymph nodes and increased the number of effectively maturated antigen‐presenting cells after subcutaneous injection in vivo. Consequently, cholesteryl‐linked methacrylamide‐based polymers with pH‐sensitive 2‐propionic‐3‐methylmaleic anhydride side groups provide ideal features for immunodrug delivery.
Automated Microfluidics‐Assisted Hydrogel‐Based Wet‐Spinning for the Biofabrication of Biomimetic Engineered Myotendinous Junction
Authors: Marina Volpi, Alessia Paradiso, Ewa Walejewska, Cesare Gargioli, Marco Costantini, Wojciech Swieszkowski
Journal: Advanced Healthcare Materials (2024)

Abstract The muscle‐tendon junction (MTJ) plays a pivotal role in efficiently converting the muscular contraction into a controlled skeletal movement through the tendon. Given its complex biomechanical intricacy, the biofabrication of such tissue interface represents a significant challenge in the field of musculoskeletal tissue engineering. Herein, a novel method to produce MTJ‐like hydrogel yarns using a microfluidics‐assisted 3D rotary wet‐spinning strategy is developed. Optimization of flow rates, rotational speed, and delivery time of bioinks enables the production of highly compartmentalized scaffolds that recapitulate the muscle, tendon, and the transient MTJ‐like region. Additionally, such biofabrication parameters are validated in terms of cellular response by promoting an optimal uniaxial alignment for both muscle and tendon precursor cells. By sequentially wet‐spinning C2C12 myoblasts and NIH 3T3 fibroblasts, a gradient‐patterned cellular arrangement mirroring the intrinsic biological heterogeneity of the MTJ is successfully obtained. The immunofluorescence assessment further reveals the localized expression of tissue‐specific markers, including myosin heavy chain and collagen type I/III, which demonstrate muscle and tenogenic tissue maturation, respectively. Remarkably, the muscle‐tendon transition zone exhibits finger‐like projection of the multinucleated myotubes in the tenogenic compartment, epitomizing the MTJ signature architecture.
Advances in Human Cellular Mechanistic Understanding and Drug Discovery of Brain Organoids for Neurodegenerative Diseases
Authors: Tong Lei, Xiaoshuang Zhang, Gaoshuang Fu, Shanglin Cai, Wangyu Bi, Shiwen Deng, Caifeng Li, Zhao Cui, Junxian Cao, Hongjun Yang, Peng Chen
Journal: Ageing Research Reviews (2024)
Urinary biomarkers associated with pathogenic pathways reflecting histological findings in lupus nephritis
Authors: Kazuoto Hiramoto, Shuntaro Saito, Hironari Hanaoka, Jun Kikuchi, Hiroyuki Fukui, Akinori Hashiguchi, Katsuya Suzuki, Tsutomu Takeuchi, Yuko Kaneko
Journal: Arthritis & Rheumatology (2024)

Objective There is a pressing need to understand the pathogenesis of histological findings and identify the biomarkers for predicting the histological severity in lupus nephritis (LN). This study aimed to identify the pathogenic signal pathway and elucidate urinary biomarkers for predicting the presence or severity of histological findings in LN. Methods Urine samples from patients with biopsy‐proven active LN were screened for 1305 proteins using an aptamer‐based proteomic assay. The diversity and expansion of individual renal histological features in LN were quantified to identify the urinary proteins associated with the histological findings found in each score. Candidate urinary proteins were validated in a validation cohort. Immunohistochemical staining of the renal tissues was performed to clarify the localisation of the candidate proteins. Results Cluster analysis extracted five histological subgroups according to their correlations with each histological finding in LN. Protein groups which correlated with each histological subgroup revealed a distinct pathogenesis in LN using pathway analyses. Enzyme‐linked immunosorbent assay validation revealed that urinary calgranulin B (S100A9), MCP‐1, and IGFBP‐5 levels could specifically predict the presence and severity of active glomerular lesions, interstitial inflammation, and interstitial fibrosis, respectively. Immunohistochemical staining revealed the localisation of these proteins in each lesion. Conclusions Renal histological findings may reflect the different pathogeneses involved in each lesion, and estimating the urinary calgranulin B, MCP‐1, and IGFBP‐5 levels may be useful in predicting the presence and severity of histological findings in LN.
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Authors: Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale, Timothy Rolph, Raymond T Chung, Raj Vuppalanchi, Kenneth Cusi, Rohit Loomba, Michele Pansini, Andrea Dennis
Journal: Journal of Hepatology (2024)
Risk of recurrence in screen-versus non screen-detected colorectal cancer patients
Authors: J K F Pluimers, P H A Wisse, M E van Leerdam, E Dekker, I van Lansdorp-Vogelaar, P J Tanis, M A G Elferink, C M den Hoed, M C W Spaander
Journal: Clinical Gastroenterology and Hepatology (2024)
Effect of adequacy of empirical antibiotic therapy for hospital-acquired bloodstream infections on ICU patient prognosis: a causal inference approach using data from the Eurobact2 study
Authors: Ambre Loiodice, Sébastien Bailly, Stéphane Ruckly, Niccolò Buetti, François Barbier, Quentin Staiquly, Alexis Tabah, Jean-François Timsit
Journal: Clinical Microbiology and Infection (2024)
Hepatocyte Aquaporin 8-mediated Water Transport Facilitates Bile Dilution and Prevents Gallstone Formation in Mice
Authors: Xiaokui Huo, Zhenlong Yu, Feng Zhao, Yang Chen, Peng Chen, Lina Xing, Yanling Qiao, Yulin Peng, Manman Tian, Meirong Zhou, Fan Wu, Yan Wang, Chao Wang, Xiangge Tian, Dongyue Lv, Bo Zhang, Lei Shi, Xiaochi Ma, Tonghui Ma
Journal: Journal of Hepatology (2024)
Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study
Authors: Fariyo Abdullahi, Marta Bertran, Joshua C D'Aeth, Seyi Eletu, Yung-Wai Chan, Nick J Andrews, David J Litt, Mary E Ramsay, Shamez N Ladhani
Journal: The Lancet Child & Adolescent Health (2024)

On Jan 1, 2020, the UK transitioned from a 2+1 to a 1+1 national infant immunisation schedule with the 13-valent pneumococcal conjugate vaccine (PCV13). We assessed whether the 1+1 PCV13 schedule had any impact on incidence, disease characteristics, or outcomes after invasive pneumococcal disease (IPD) in eligible children aged 0-3 years.
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis
Authors: Robert J Commons, Megha Rajasekhar, Elizabeth N Allen, Daniel Yilma, Palang Chotsiri, Tesfay Abreha, Ishag Adam, Ghulam Rahim Awab, Bridget E Barber, Larissa W Brasil, Cindy S Chu, Liwang Cui, Peta Edler, Margarete do Socorro M Gomes, Lilia Gonzalez-Ceron, Matthew J Grigg, Muzamil Mahdi Abdel Hamid, Jimee Hwang, Harin Karunajeewa, Marcus V G Lacerda, Simone Ladeia-Andrade, Toby Leslie, Rhea J Longley, Wuelton Marcelo Monteiro, Ayodhia Pitaloka Pasaribu, Jeanne Rini Poespoprodjo, Caitlin L Richmond, Komal Raj Rijal, Walter R J Taylor, Pham Vinh Thanh, Kamala Thriemer, José Luiz F Vieira, Nicholas J White, Lina M Zuluaga-Idarraga, Lesley J Workman, Joel Tarning, Kasia Stepniewska, Philippe J Guerin, Julie A Simpson, Karen I Barnes, Ric N Price
Journal: The Lancet Child & Adolescent Health (2024)

Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we aimed to determine the efficacy and safety of different primaquine dose strategies in children younger than 15 years.
Intimate partner violence and childhood health outcomes in 37 sub-Saharan African countries: an analysis of demographic health survey data from 2011 to 2022
Authors: Abel F Dadi, Kedir Y Ahmed, Yemane Berhane, Habtamu Mellie Bizuayehu, Getayeneh Antehunegn Tesema, Tahir A Hassen, Getiye Dejenu Kibret, Daniel Bekele Ketema, Meless G Bore, Sewunet Admasu Belachew, Erkihun Amsalu, Sergio Nhassengo, Desalegn Markos Shifti, Abdulbasit Seid, Yonatan M Mesfin, Teketo Kassaw Tegegne, Daniel Bogale Odo, Zemenu Yohannes Kassa, Subash Thapa, Eshetu Girma Kidane, Hanna Demelash Desyibelew, Awoke Misganaw, Berihun M Zeleke, Obasanjo Afolabi Bolarinwa, Allen G Ross
Journal: The Lancet Global Health (2024)

Understanding the contribution of intimate partner violence (IPV) to childhood health outcomes (eg, morbidity and mortality) is crucial for improving child survival in sub-Saharan Africa. This comprehensive study aimed to explore the associations between maternal exposure to physical, sexual, or emotional violence and adverse childhood health outcomes in sub-Saharan Africa.
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial
Authors: Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy
Journal: The Lancet Infectious Diseases (2024)
Health and humanitarian toll of Sudan's forgotten war
Authors: Ezzeldin Saleh, Khalid M Dousa, Ahmed Babiker, Nour Elhouda At Alla Rahma, Hamad Abdel Hadi, Mustafa Elsayed, Suleima Ishag Elkhalifa, Sami Mahmoud Abdelkhair Momin, Ahmed Abubaker, Omer Mergani Nemery, Luai Mohmmed Bashir, Shahinaz Bedri, Nada Fadul, Yasir Hamad, Zahir Osman Eltahir Babiker
Journal: The Lancet (2024)
Randomized controlled trial of artificial intelligence diagnostic system in clinical practice to detect esophageal squamous cell carcinoma
Authors: Eisuke Nakao, Toshiyuki Yoshio, Yusuke Kato, Ken Namikawa, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiaki Hirasawa, Nozomi Kurihara, Naoki Ishizuka, Ryu Ishihara, Tomohiro Tada, Junko Fujisaki
Journal: Endoscopy (2024)

Abstract Background Artificial intelligence (AI) has made remarkable progress in image recognition using deep learning systems. It has been used to detect esophageal squamous cell carcinoma (ESCC); however, none of the previous reports were investigations in a clinical setting, being retrospective in design. We therefore conducted this trial to determine how AI can help endoscopists detect ESCC in a clinical setting. Methods This was a prospective, single-center, exploratory, and randomized controlled trial. High risk patients with ESCC undergoing screening or surveillance esophagogastroduodenoscopy were enrolled and randomly assigned to either the AI or control groups. In the AI group, the endoscopists watched both the AI monitor that detected ESCC with annotation and the normal monitor simultaneously; in the control group, the endoscopists watched only the normal monitor. In both groups, the endoscopists observed the esophagus using white-light imaging (WLI), followed by narrow-band imaging (NBI), then iodine staining. The primary end point was the enhanced detection rate of ESCC by nonexperts using AI. The detection rate was defined as the ratio of WLI/NBI-detected ESCCs to all ESCCs detected by iodine staining. Results 320 patients were included in the analysis. The detection rate of ESCC among nonexperts was 47% in the AI group and 45% in the control group (P = 0.93), with no significant difference, which was similarly found for experts (87% vs. 57%; P = 0.20) and all endoscopists (57% vs. 50%; P = 0.70). Conclusions This study could not demonstrate an improvement in the esophageal cancer detection rate using the AI diagnostic support system for ESCC.
Clinical sequelae of gut microbiome development and disruption in hospitalized preterm infants
Authors: Robert Thänert, Drew J. Schwartz, Eric C. Keen, Carla Hall-Moore, Bin Wang, Nurmohammad Shaikh, Jie Ning, L. Colleen Rouggly-Nickless, Anna Thänert, Aura Ferreiro, Skye R.S. Fishbein, Janice E. Sullivan, Paula Radmacher, Marilyn Escobedo, Barbara B. Warner, Phillip I. Tarr, Gautam Dantas
Journal: Cell Host & Microbe (2024)
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study
Authors: Hiroji Shinkawa, Masaki Kaibori, Masaki Ueno, Satoshi Yasuda, Hisashi Ikoma, Tsukasa Aihara, Takuya Nakai, Masahiko Kinoshita, Hisashi Kosaka, Shinya Hayami, Yasuko Matsuo, Ryo Morimura, Takayoshi Nakajima, Chihoko Nobori, Takeaki Ishizawa
Journal: Liver Cancer (2024)

Introduction: This study aimed to evaluate the association of obesity and diabetes mellitus (DM) comorbidity with hepatocellular carcinoma (HCC) recurrence and survival. Methods: We investigated 1,644 patients who underwent hepatic resection for solitary HCC without vascular invasion using computed tomography. Patients were categorized into four groups according to the combination of obesity and DM comorbidities: OB (+) or (−) and DM (+) or (−). Postoperative cumulative recurrence rates within and beyond 2 years and beyond 5 years were assessed. Results: Multivariate Cox proportional hazard regression analysis revealed that the adjusted hazard ratios (HRs) of reduced recurrence-free survival was 1.10 (95% confidence interval [CI]: 0.91–1.33; p = 0.31), 0.94 (95% CI: 0.78–1.12; p = 0.48), and 1.24 (95% CI: 1.01–1.54; p = 0.045) in the OB(+)DM(−), OB(−)DM(+), and OB(+)DM(+) groups compared with the OB(−)DM(−) group, respectively. Additionally, the corresponding adjusted HRs of reduced overall survival were 0.93 (p = 0.57), 0.97 (p = 0.76), and 1.38 (p = 0.013) for OB(+)DM(−), OB(−)DM(+), and OB(+)DM(+) groups, respectively. No significant difference in the early recurrence rate was determined among the four groups. The OB(+)DM(+) group demonstrated an increased risk for late recurrence beyond 2 years and 5 years postoperatively compared with the OB(−)DM(−) group (HR: 1.51; p = 0.024 and HR: 2.53; p = 0.046, respectively). The OB(+)DM(−) and OB(−)DM(+) groups demonstrated an increased risk for late recurrence beyond 5 years postoperatively (HR: 3.83; p &amp;lt; 0.001 and HR: 1.95; p = 0.037, respectively). Conclusions: Obesity and DM coexistence increased late recurrence and worsened prognosis in patients with HCC undergoing hepatic resection. The results help surgeons develop possible different surveillance protocol and need to focus on diabetes/obesity control during life-long surveillance for patients with HCC.
Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled Trial
Authors: Kadambari Vijaykumar, George M Solomon, Jennifer Guimbellot, Edward P Acosta, Pradeep G. Bhambhavni, Sharon White, Harrison Kim, S. Vamsee Raju, Lawrence W. Rasmussen, Necole Harris, Bo Liu, Heather Hathorne, Steven M Rowe, Mark T. Dransfield
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Patients with chronic obstructive pulmonary disease (COPD) exhibit acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. CFTR modulators may improve outcomes in patients with COPD, although recent data regarding magnitude of benefit have been inconclusive and effects on mucociliary clearance are unknown. We conducted a phase 2, randomized, double blind placebo control trial to determine safety and tolerability, and explore the potential mechanism of ivacaftor for the treatment of COPD.
A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort
Authors: Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman, Alejandro Sica, Noah Kornblum, Nishi Shah, David Levitz, Bradley Rockwell, Lauren C Shapiro, Ridhi Gupta, Kith Pradhan, Xiaonan Xue, Anne Munoz, Aradhika Dhawan, Karen Fehn, Monica Comas, Jhannine Alyssa Verceles, Brian A. Jonas, Suman Kambhampati, Yang Shi, Ira Braunschweig, Dennis L Cooper, Marina Y. Konopleva, Eric J Feldman, Amit Verma
Journal: Blood (2024)
The Genomic Landscape of Benign and Malignant Thyroid Tumors from Individuals Carrying Germline <i>PTEN</i> Variants Is Distinct from Sporadic Thyroid Cancers
Authors: Gilman Plitt, Takae Brewer, Lamis Yehia, Laura Rabinowitz, Christopher C. Griffith, Charis Eng
Journal: Cancer Research (2024)

Abstract Patients with PTEN hamartoma tumor syndrome (PHTS), a molecular diagnosis for those carrying germline PTEN pathogenic variants, have a high prevalence of benign and malignant thyroid disease. Characterizing the genomic landscape in PHTS thyroid tumors could provide insights into malignant potential and tumor progression to help optimize diagnosis, surveillance, and treatment in this population. To reveal the somatic alterations in PHTS-associated thyroid tumors, we conducted exome sequencing on 58 thyroid tumors (28 cancers, 30 benign nodules) from 19 patients with PHTS. A control cohort of 447 sporadic papillary thyroid cancers (PTC) from The Cancer Genome Atlas was used for comparison. PHTS-associated thyroid tumors had a unique genomic landscape in the setting of a pathogenic germline PTEN mutation, when compared with the general population. PHTS-associated thyroid tumors demonstrated a high frequency of second-hit somatic PTEN alterations, including variants and loss-of-heterozygosity events. Second-hit somatic PTEN alterations were more prevalent in PHTS-associated PTC than sporadic PTC (65.2% vs. 0.067%), occurring frequently in PHTS-associated follicular thyroid cancer (100%) and benign follicular nodules (90%). PHTS-associated PTC additionally harbored somatic alterations in BRAF, RAS family members, and genes associated with DNA double-stranded break repair, as well as somatic arm-level copy-number variations. Together, these findings suggest that biallelic PTEN alterations may function as foundational mutations in PHTS thyroid tissue, promoting benign growth and increasing potential for malignant transformation through impaired DNA double-stranded break repair and increased genomic instability. The unique genomic landscape of PHTS-associated thyroid tumors carries implications for molecular-targeted therapies for patients. Significance: Exome sequencing reveals the distinct mutational landscape of PTEN hamartoma tumor syndrome–associated thyroid cancers from sporadic counterparts, providing insights into tumor progression and behavior that could help improve diagnosis, surveillance, and treatment.
Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescuing and cancer mutations
Authors: Fernanda Gutierrez-Rodrigues, Emma M Groarke, Natthakan Thongon, Juan Jose Rodriguez-Sevilla, Luiz Fernando Bazzo Catto, Marena Rebekka Niewisch, Ruba N Shalhoub, Lisa J. McReynolds, Diego V Clé, Bhavisha A. Patel, Xiaoyang Ma, Dalton Hironaka, Flavia S Donaires, Nina R Spitofsky, Barbara A. Santana, Tsung-Po Lai, Lemlem Alemu, Sachiko Kajigaya, Ivana Darden, Weiyin Zhou, Paul V. Browne, Subrata Paul, Justin Lack, David J. Young, Courtney D. DiNardo, Abraham Aviv, Feiyang Ma, Michel Michels de Oliveira, Ana Paula de Azambuja, Cynthia E. Dunbar, Malgorzata Olszewska, Emmanuel Olivier, Eirini P Papapetrou, Neelam Giri, Blanche P. Alter, Carmem M.S. Bonfim, Colin O. Wu, Guillermo Garcia-Manero, Sharon A Savage, Neal S. Young, Simona Colla, Rodrigo T. Calado
Journal: Blood (2024)
Advancing Global Health Equity in Oncology Clinical Trial Access
Authors: Tolulope Adewole, Bjorn Albrecht, Shaalan Beg, Otis Brawley, I-Fen Chang, Bobby Daly, Angelo de Claro, Jennifer Dent, Maura Dickler, Abasi Ene-Obong, Lola Fashoyin-Aje, Justin Finnegan, Susan Galbraith, Mary Gospodarowicz, Julie Gralow, Tufia Haddad, Chitkala Kalidas, Artur Katz, Karen Kaucic, Harriet Keane, Mark Lanasa, Jeff Legos, Bob T. Li, Jennifer Mills, Stefan Oelrich, Stefan Olopade, John Palma, Richard Pazdur, Piotr Pilarski, Jing Qian, Kevin Rudd, Sepideh Shokrpour, Craig Tendler, Matt Wilson, Victoria W. Smart, Yi-Long Wu, James Yan, Lianshan Zhang, Diya Li, Johanna Shen, Amy Silverstein, Ghassan Abou-Alfa, Shelly Anderson, Patrick Beyrer, Danielle Carnival, Stephen Clarke, Terri Conneran, Lisa M. DeAngelis, Connie Diakos, Luis Diaz, Carlos Henrique dos Anjos, Jeffrey A. Drebin, Debra Eisenmen, Russell Flannery, David Fredrickson, James M. Isbell, David R. Jones, Adedayo Joseph, Caroline Kennedy, T. Peter Kingham, Adrian Lee, Nancy Y. Lee, Lillian Leigh, Zhi-Zhong Li, An-Wen Liu, Dazhi Liu, Si-Yang Liu, Si-Yang Maggie Liu, Vicky Makker, Meritxell Mallafre-Larrosa, Sean McBride, Isabel Mestres, Sebastian Mondaca, Paulo Nigro, Larry Norton, John V. Oyler, Nick Pavlakis, Simon Powell, Bruce Robinson, Yi Qin, Pedram Razavi, Jorge Reis-Filho, Gaetano Rocco, Charles M. Rudin, Orville Schell, Howard I. Scher, Deborah Schrag, Greg Simon, Dorrance Smith, Morgan Speece, Hai-Yan Tu, Aminu Umar-Sadiq, Bu-Hai Wang, Helen Wheeler, Chong-Rui Xu, Li-Xu Yan, Fan Yang, Byeong Yoon, Catharine Young, Jia-Tao Zhang, Qing Zhou
Journal: Cancer Discovery (2024)

Summary: Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global “hub-and-spoke” network model to expand access to and accelerate clinical trials, thus ending cancer as a major cause of death in this lifetime.
Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia
Authors: Sunniyat Rahman, Gianna Bloye, Nadine Farah, Jonas Demeulemeester, Joana R Costa, David O'Connor, Rachael Pocock, Tanya Rapoz-D'Silva, Adam Turna, Lingyi Wang, Soo Wah Lee, Adele K Fielding, Juliette Roels, Roman Jaksik, Małgorzata Dawidowska, Pieter Van Vlierberghe, Suzana Hadjur, Jim R Hughes, James Davies, Alejandro Gutierrez, Michelle Kelliher, Peter Van Loo, Mark A. Dawson, Marc R. Mansour
Journal: Blood (2024)